Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digi...
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
INCHEON, South Korea and SUZHOU, China, Nov. 1, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma ...
Samsung Biologics expands global footprint with opening of new San Francisco CDO R&D Center
INCHEON, South Korea and SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- At a virtual ceremony today, Samsung Biologics (KRX: 207940.KS) announced the grand opening of its first US CDO R&D Center inSan Francisco, bringing its contract development services closer to global clients. As the "Next Door ...
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clini...
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing
INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. Under this agreement, Samsung Biologics will provide a full scope of its ...
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to ta...
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...
Samsung Biologics launches S-CHOice cell line expression technology
INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) today held an online ceremony to announce the launch of its
proprietary cell line technology, S-CHOice.
Samsung Biologics Posts Strong Second Quarter Earnings With 48.5% Increase In Sales
INCHEON, South Korea, July 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) announced today strong financial results for its fiscal 2020 second
quarter endingJune 30, 2020, maintaining steady business performance with a
high operating margin at 26.4%.
Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon
SONGDO, South Korea, July 20, 2020 /PRNewswire/ -- Samsung Biologics
(207940.KS) announced a plan to expand its Drug Product (DP) capability in line
with increasing market demand and to ensure flexible production capabilities
for new and existing clients.
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018. ...
Samsung Biologics signs additional development and manufacturing agreement with STCube
SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopha...
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...
Samsung Biologics Expands Business Continuity Excellence with Additional ISO22301 Certification
SONGDO, South Korea, May 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business...
Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)
SONGDO, South Korea, April 22, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018. As a result, ImmuneOncia will begin Phase 1 ...
Samsung Biologics Earnings to Beat Consensus Again, Continues to Sign New Projects with Enhanced Virtual Support
SONGDO, South Korea, April 22, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced Q1 earnings results onMonday, April 20th. The company posted consolidated sales of207.2 billion Korean Won, operating profit of 62.6 billion Korean Won, and net income of 39.1 billion Korean Won. The ...
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment
SONGDO, South Korea and SAN FRANCISCO, April 9, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal anti...
